摘要
长链非编码RNA（long non-coding RNA,lncRNA）是非编码RNA的一个大类,其在多种肿瘤中异常表达。近年来,不少研究发现lncRNA,如ROR、HOTAIR、UCA1、BCAR4,在雌激素受体阳性（ER＋）乳腺癌的他莫昔芬耐药中发挥了重要作用。因此,了解lncRNA在他莫昔芬耐药中的生物学机制具有重要的临床意义。该文就lncRNA与ER＋乳腺癌他莫昔芬耐药的相关研究展开综述,为ER＋乳腺癌他莫昔芬耐药的预防及治疗提供新思路。
Long non-coding RNA（lncRNA） is a large class of non-coding RNA,which is abnormal in multiple tumors. In recent years,many studies have found that lncRNAs,such as ROR,HOTAIR,UCA1 and BCAR4,play an important role in drug resistance of tamoxifen in ER ＋ breast cancer.Therefore,it is of great clinical significance to understand the biological mechanism of lncRNA in tamoxifen resistance. In this article,the related studies of lncRNA and tamoxifen resistance in ER＋breast cancer are reviewed to provid new thoughts to the prevention and treatment for ER ＋ breast cancer with tamoxifen resistance.
作者
梁国华
张清媛
赵文辉
LIANG Guo-hua;ZHANG Qing-yuan;ZHAO Wen-hui(Harbin Medical University Cancer Hospital,Harbin 150081,China)
出处
《中国肿瘤》
CAS
CSCD
北大核心
2018年第9期690-694,共5页
China Cancer
